Interestingly, Wang et al [37] identified autosecretion of GM-CSF as a mechanism that allowed CML cells to resist imatinib and nilotinib treatment in vitro. This evidence concerns the gene CSF2 and chronic myelogenous leukemia, BCR-ABL1 positive.